期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

阿尔茨海默病相关生物标志物的研究现状及进展 被引量：1

下载PDF
导出
摘要 阿尔茨海默病（Alzheimer＇s disease,AD）是一种中枢神经系统常见的、进行性神经退行性疾病,主要病理特征为脑神经细胞外老年斑（senile plaques,SP）和脑神经细胞内神经纤维缠结（neurofibrillary tangles,NFTs）。AD的发病机制非常复杂,迄今尚未完全明确。普遍认为AD为多因素影响的综合征,患者的年龄和家族史为最大致病危险因素。
作者 李锡海 于明 吴金美
机构地区 江苏科技大学生物技术学院 江苏大学附属医院神经内科
出处 《江苏大学学报（医学版）》 CAS 2013年第1期84-88,共5页 Journal of Jiangsu University：Medicine Edition
关键词 阿尔茨海默病 早期诊断 生物标志物
分类号 R741.04 [医药卫生—神经病学与精神病学]
  • 相关文献

参考文献41

  • 1Hampel H, Shen Y, Walsh DM, et al. Biological markers of amyloid beta-related mechanisms in Alzheimer's disease [J]. ExpNeurol, 2010, 223(2): 334-346.
  • 2Simonsen AH, Hansson SF, Ruetschi U, et al. Amyloid beta 140 quantification in CSF: comparison between chro- matographic and immunochemical methods [ J]. Dement Geriatr Cogn Disord, 2007, 23 (4) : 246 - 250.
  • 3Tarawneh R, Holtzman DM. Biomarkers in translational research of Alzheimer's disease[ J]. Neuropharmacology, 2010, 59(4/5): 310-322.
  • 4Gloeckner SF, Meyne F, Wagner F, et al. Quantitative a- nalysis of transthyretin, tau and amyloid-beta in patients with dementia[J]. J Alzheimers Dis, 2008, 14( 1 ) : 17 - 25.
  • 5Kanai M, Matsubara E, Isoe K, et al. Longitudinal study of cerebrospinal fluid levels of tau, A beta 1-40, and A beta 1-42 (43) in Alzheimer's disease: a study in Japan [J]. AnnNeurol, 1998, 44(1): 17-26.
  • 6Wiltfang J, Esselmann H, Bibl M, et al. Amyloid beta peptide ratio 42/40 but not A beta 42 correlates with phospho-Tau in patients with-low and high-CSF A beta 40 load[J]. J Neurochem, 2007, 101(4):1053-1059.
  • 7Ertekin-Taner N, Younkin LH, Yager DM, et al. Plasma amyloid beta protein is elevated in late-onset Alzheimer disease families [ J ]. Neurology, 2008, 70 (8) : 596 - 606.
  • 8Lewczuk P, Kornhuber J, Vanmechelen E, et al. Amyloid beta peptides in plasma in early diagnosis of Alzheimer's disease: A multicenter study with multiplexing[ J]. Exp Neurol, 2010, 223(2) : 366 -370.
  • 9Fukumoto H, Tennis M, Locascio J J, et al. Age but not diagnosis is the main predictor of plasma amyloid beta- protein levels [ J ]. Arch Neurol, 2003, 60 (7) : 958 - 964.
  • 10彭丹涛,许贤豪,孟晓梅,刘江红,谢琰臣,冯凯.老年性痴呆血浆中Aβ1-42、Aβ1-40及p-tau(^(181)P)蛋白的临床诊断意义[J].中国神经免疫学和神经病学杂志,2005,12(4):208-211. 被引量：13

二级参考文献9

  • 1Etsuro M, Mikio S, Koji A, et al. Vascular amyloidosis in neurodegenerative condition[J]. Drugs News Perspect, 2002,15:439-444.
  • 2Kuo YM, Emmerling MR, Lapert HC, et al. High levels of circulating A beta42 are sequestered by plasma proteins in AD[J].Biochem Biophys Res Commun, 1999,257: 787-794.
  • 3刘世杰 王建枝.Tau蛋白的结构、功能和异常修饰与阿尔茨海默病的关系[M].见:盛树力.老年性痴呆:发病机理与药物研究[M].北京:科学技术文献出版社,2003.107-119.
  • 4Gong CX, Lidsky T, Wegiel J, et al. Phosphorylation of microtubule-associated protein tau is regulated by protein phosphatase 2A in mammalian brain implications for neurofibrillary degeneration in Alzheimer's disease[J]. J Biochem, 2000,275(8): 5535-5544.
  • 5Thurston VC, Zinkowski RP, Binder LI. Tau as a nucleolar protein in human nonneural cell in vitro and in vivo[J]. Chromosoma, 1996,105:20-30.
  • 6Martin I, Mari B, Eirikur B, et al. Tau immunoreactivity detected in human plasma, but no obvious increase in dementia[J]. Dement Geriatr Cogn Disord, 1999,10:442-445.
  • 7Hampel H, Goernitz A, Buerger K. Advances in the development of biomarkers for Alzheimer disease: from CSF total tau and Aβ1-42 ptroteins to phosphorylated tau protein[J]. Brain Res Bull, 2003,61(3): 243-253.
  • 8Hampel H, Buerger K, Zinkowski R, et al. Measurement of phosphorylated tau epitopes differential diagnosis of Alzheimer disease comparative cerebrospinal fluid study[J], Arch Gen Psychiatry, 2004,61(1): 95-102.
  • 9Andreasen N, Sjogren M, Blennow K. CSF marker for Alzheimer disease: total tau, phospho-tau and Aβ42[J]. World J Biol Psychiatry, 2003,4(4): 147-155.

共引文献12

同被引文献1

引证文献1

二级引证文献3

江苏大学学报（医学版）
2013年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部